BioCentury
ARTICLE | Clinical News

ACH-3102: Phase I data

November 19, 2012 8:00 AM UTC

A Phase I drug-drug interaction study in 24 healthy volunteers showed there was no interaction between sovaprevir and ACH-3102. The combination was well tolerated with no significant adverse events reported. Data were presented at the American Association for the Study of Liver Diseases meeting in Boston. ...